Physician profile
Carlos E Diaz
NPI 1083687917
$1,070.83
in general payments reported to CMS, 2019-2025
11 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Pediatric Pulmonology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.74 · 2020: $39.23 · 2021: $464 · 2022: $383 · 2023: $57.34 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $155 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $155.06 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $382.96 | 2022 | |
| Medtronic, INC. | $301.73 | 2021 | |
| Intercept Pharmaceuticals, INC. | $92.71 | 2021-2023 | Ocaliva |
| Abbvie INC. | $91.95 | 2021-2025 | |
| Sobi, INC | $51.42 | 2021 | |
| Allergan, INC. | $39.23 | 2020 | |
| Janssen Biotech, INC. | $32.06 | 2023 | Stelara, Remicade |
| Celgene Corporation | $24.88 | 2021 | |
| Pfizer INC. | $24.77 | 2025 | |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Boston Scientific Corporation | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.